MedTrace Logo

Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir

NCT01032499 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2010-03-19

No results posted yet for this study

Summary

To measure the efficacy of Taro Elixir compare with Oxytetracycline in the treatment of boils or acne.

Conditions

  • Acne Vulgaris II or III Degree
  • Boils

Interventions

DRUG

oxytetracycline, taro elixir

comparison of treatment efficacy between oxytetracycline and taro elixir

DRUG

Taro Elixir

Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.

Sponsors & Collaborators

  • Laboratorios Goulart S.A.

    lead INDUSTRY

Principal Investigators

  • Carlos Machado · Faculdade de Medicina do ABC

  • Andrea Gerbase · Alergoclínica - Centro de Alergia e dermatologia

  • Denise Steiner · Policlínica Mogi das Cruzes

  • Jussara Marin · Alergoclínica - Centro de alergia e dermatologia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-07-31
Completion
2010-10-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01032499 on ClinicalTrials.gov